Life sciences software provider, ArisGlobal, has completed its acquisition of Amplexor Life Sciences. The move adds quality management system (QMS) capabilities to ArisGlobal’s LifeSphere drug development platform, spanning the pharmaceutical product lifecycle, including Clinical, Regulatory, Medical Affairs, and Safety. The acquisition includes the addition of a labeling management solution to the LifeSphere Regulatory platform and will also enable enhanced global submission publishing capabilities. ArisGlobal’s purchase also brings two new office locations in Croatia and Slovenia into its geographic footprint.
The leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere®, today announces the completion of its acquisition of Amplexor Life Sciences. This deal will deliver the most intelligent, connected, and comprehensive regulatory platform available, bringing increased efficiency for life sciences organizations as they bring new therapies to market.
LifeSphere Quality represents an expansion of ArisGlobal’s interconnected drug development platform that spans the pharmaceutical product lifecycle including Clinical, Regulatory, Medical Affairs and Safety. Robust quality management system (QMS) capabilities, including automated workflows and analytics, are now available to support customers’ global regulatory compliance needs.
The acquisition also rounds out the end-to-end LifeSphere Regulatory platform with the addition of a labeling management solution and accelerates the Regulatory product roadmap through the integration of enhanced global submission publishing capabilities.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
ArisGlobal’s intent to purchase was previously announced in late February 2023, and brings two new office locations in Croatia and Slovenia into ArisGlobal’s geographic footprint.
Source: BioSpace